Madrigal Pharmaceuticals Inc (MDGL)

May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com

May 26, 2025

May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK

May 26, 2025

May 23, 2025

When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com

May 23, 2025

May 17, 2025

In Search Of Tailwind, Sailing Doldrums With Madrigal Pharmaceuticals Stock (MDGL) - Seeking Alpha

May 17, 2025

May 13, 2025

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years - AOL.com

May 13, 2025

May 13, 2025

Transcript : Madrigal Pharmaceuticals, Inc.Special Call - marketscreener.com

May 13, 2025

May 13, 2025

Where are the Opportunities in (MDGL) - news.stocktradersdaily.com

May 13, 2025

May 13, 2025

Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis - MSN

May 13, 2025

May 11, 2025

Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock - MSN

May 11, 2025

May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra - GuruFocus

May 11, 2025

May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News - GuruFocus

May 11, 2025

May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - The Manila Times

May 10, 2025

May 10, 2025

Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis - marketscreener.com

May 10, 2025

May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewswire Inc.

May 10, 2025

May 08, 2025

Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential - Yahoo Finance

May 08, 2025

May 08, 2025

Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential - Insider Monkey

May 08, 2025

May 07, 2025

Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey

May 07, 2025

May 06, 2025

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra (NASDAQ:MDGL) - Seeking Alpha

May 06, 2025

May 06, 2025

Billionaire John Paulson’s 10 Stocks with Huge Upside Potential - Insider Monkey

May 06, 2025

May 04, 2025

Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st

May 04, 2025

May 03, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025

May 03, 2025

Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus

May 03, 2025

May 02, 2025

(MDGL) Trading Signals - news.stocktradersdaily.com

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raise - GuruFocus

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord - GuruFocus

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost fr - GuruFocus

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News - GuruFocus

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Stron - GuruFocus

May 02, 2025

May 02, 2025

UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | - GuruFocus

May 02, 2025

May 02, 2025

UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | MDGL Stock News - GuruFocus

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Strong Sales | MDGL Stock News - GuruFocus

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN

May 02, 2025

May 02, 2025

UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating - marketscreener.com

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives Increased Price Target from Analyst | MDGL Stock News - GuruFocus

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

May 02, 2025

May 02, 2025

Madrigal Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks

May 02, 2025

May 01, 2025

Madrigal: Q1 Earnings Snapshot - Huron Daily Tribune

May 01, 2025

May 01, 2025

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Zacks Investment Research

May 01, 2025

May 01, 2025

Madrigal Pharmaceuticals Q1 Loss Narrows - marketscreener.com

May 01, 2025

May 01, 2025

Earnings call transcript: Madrigal Pharmaceuticals beats Q1 2025 EPS forecasts - Investing.com

May 01, 2025

May 01, 2025

Madrigal Pharmaceuticals Inc Q1 2025 Earnings: Revenue Surpasses - GuruFocus

May 01, 2025

May 01, 2025

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times

May 01, 2025

May 01, 2025

Madrigal Pharmaceuticals (MDGL) Reports Strong Q1 Revenue Exceed - GuruFocus

May 01, 2025

May 01, 2025

Madrigal’s MASH drug sales again top Wall Street projections - Yahoo Finance

May 01, 2025

Apr 29, 2025

Madrigal stock holds neutral as 1Q revenue beats estimates By Investing.com - Investing.com Canada

Apr 29, 2025

Apr 29, 2025

Madrigal Pharmaceuticals (MDGL) to Present Key Findings at EASL - GuruFocus

Apr 29, 2025